Deltazime

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deltazime

Quick Facts

Property Description
Active ingredient Ceftazidime (usually as Ceftazidime pentahydrate)
Form Lyophilized powder for injection (Injectable solution)
Pharmacological class Third-generation cephalosporin, Beta-Lactam antibiotic
General purpose Anti-infective agent for serious bacterial infections
Origin Semisynthetic

Beta-Lactam Identity: What Type of Medicine is Ceftazidime?

Deltazime is a pharmaceutical preparation marketed as a brand containing the prescription-only active ingredient, Ceftazidime. This substance is a semisynthetic beta-lactam antibiotic, established within the medical community as a third-generation cephalosporin. Ceftazidime is clinically recognized for its profile which provides strong bactericidal (bacteria-killing) activity, making it a choice for managing systemic infections where Gram-negative pathogens are a concern. This antibiotic is utilized in hospital settings, representing a targeted approach for managing bacterial challenges.

Composition and Administration: Why is Deltazime an Injectable Solution?

The medication is manufactured as a sterile, lyophilized powder containing the active component, Ceftazidime pentahydrate, which requires reconstitution before administration. This formulation is designed for the parenteral route (intravenous or intramuscular injection). This method ensures the drug achieves rapid and high systemic concentrations necessary for efficacy, which differentiates it from antibiotics available in oral forms. Ceftazidime is primarily reserved for parenteral use due to its pharmacological profile.

General Purpose: What is the Main Benefit of This Antibiotic?

The fundamental purpose of Deltazime is to serve as an anti-infective agent for the elimination of susceptible bacterial pathogens. Its primary benefit lies in its potent, bactericidal action—killing bacteria by inhibiting cell wall synthesis—and its ability to resist common bacterial defense mechanisms. It is positioned to provide treatment for serious infections.

Regulatory References

  1. Ceftazidime Injection: MedlinePlus Drug Information

What side effects are possible with Deltazime?

Possible Side Effects and Safety Information

The safety profile for Deltazime (Ceftazidime) is formally classified in regulatory documents according to the likelihood of occurrence and the organ system affected, providing a structured overview of potential adverse reactions. All documented safety statements are based strictly on official prescribing information.


Documented Adverse Reactions

Adverse reactions are grouped by frequency as defined in regulatory labeling:

  • Common Reactions (1% to <10%): Include reactions such as diarrhea, eosinophilia (an increase in a type of white blood cell), and temporary elevations in liver enzymes. Pain or inflammation at the injection site, along with phlebitis at the intravenous site, are also commonly reported.
  • Uncommon Reactions (0.1% to <1%): These effects involve the gastrointestinal system (e.g., nausea, vomiting, abdominal pain), the nervous system (e.g., headache, dizziness), and the skin (e.g., rash, pruritus).

Reactions whose frequency is not known include severe events such as anaphylaxis, jaundice, and severe cutaneous adverse reactions like Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.


Serious Safety Considerations

Official labeling highlights the risk of serious adverse reactions, including potentially fatal anaphylaxis and severe Clostridioides difficile-associated diarrhea (CDAD). Of particular note are neurological sequelae (e.g., seizures, coma, encephalopathy), which are linked to high drug concentrations.

Regulatory documentation mandates that patients with known or suspected renal impairment receive a reduced dosage. This safety constraint is necessary to prevent drug accumulation and mitigate the risk of these dose-related neurological effects. The medicine is contraindicated in individuals with a known hypersensitivity to ceftazidime or other cephalosporins.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention is required for any suspected overdose of Deltazime due to the documented potential for severe or life-threatening cardiovascular effects. Overdose is considered a medical emergency and management should occur under close medical supervision.

Documented Overdose Manifestations

Official regulatory labeling describes overdose presentations primarily centered on profound cardiac depression. These documented clinical signs include bradycardia (abnormally slow heart rate), hypotension (low blood pressure), and atrioventricular (AV) conduction disturbances such as first-, second-, or third-degree AV block. Severe outcomes officially noted include the risk of cardiac failure, refractory shock, and asystole (cardiac arrest).

Official Management and Observation

Regulatory documents mandate that treatment be symptomatic and supportive. Supportive measures detailed in official labeling include gastrointestinal decontamination (e.g., activated charcoal) and specific pharmacological interventions. These may include the administration of atropine or vasopressors to manage hypotension, and specialized interventions such as cardiac pacing for fixed high-degree AV block. Continuous ECG monitoring is required to assess cardiac conduction and guide treatment.

Overdose involving extended-release formulations is a critical consideration, as drug release may be delayed. Regulatory information requires prolonged observation for these formulations due to the risk of delayed onset or relapse of severe cardiotoxicity.

Therapeutic Uses of Deltazime

Quick Facts: Uses of Deltazime

  • Management of Elevated Blood Pressure: Helps to support healthy blood pressure levels.
  • Support for Angina Pectoris: Assists in the long-term management of chronic chest discomfort.
  • Helps Chronic Stable Angina: Contributes to improved capacity for physical activity in individuals with this condition.
  • Assists in Certain Arrhythmias: Used to help regulate rapid ventricular rate in conditions like atrial fibrillation or atrial flutter.

Deltazime is a prescription medication utilized in the management of various cardiovascular conditions. Its main therapeutic uses are centered on addressing high blood pressure and specific forms of heart-related chest discomfort.

For those managing elevated blood pressure (hypertension), Deltazime provides support to promote healthy blood pressure regulation. Maintaining healthy blood pressure is an important element of a comprehensive cardiovascular risk management plan.

In the context of heart disease, Deltazime is indicated for the management of chronic stable angina, a condition associated with recurring chest discomfort. The treatment helps to promote an increased ability to engage in physical activity. It is also used in the management of angina resulting from coronary artery spasm. Furthermore, this medication assists in the management of certain heart rhythm irregularities (arrhythmias), such as helping to control the rate in atrial fibrillation or flutter.

Eligibility and Restrictions for Use

The eligibility for Deltazime (Diltiazem) is defined by regulatory agencies based on cardiovascular health status and specific patient demographics, establishing absolute non-eligibility and conditional use.

Eligibility Status Applicable Population or Condition
Contraindicated (Must Not Use) Patients with demonstrated hypersensitivity to the drug. Sick Sinus Syndrome or Second-/Third-Degree AV Block, except where a functioning ventricular pacemaker is present. Severe hypotension or Acute Myocardial Infarction with Pulmonary Congestion.
Use Not Established The pediatric population (children and adolescents). Safety and effectiveness have not been formally established in this age group.
Use with Caution (Restricted) Patients with impaired hepatic (liver) or renal (kidney) function. Use requires monitoring due to the drug's metabolism and elimination. Patients with Congestive Heart Failure should use with caution.
Conditional Use Pregnant women, where use is not generally recommended unless the potential maternal benefit is determined to outweigh the potential fetal risk.

This regulatory structure defines who is formally excluded from treatment and mandates caution or special monitoring for specific populations, such as those with organ impairment.

What should I know about interactions with other medicines?

The interaction profile for Deltazime is primarily defined by two regulatory classifications: pharmacokinetic effects on drug metabolism and pharmacodynamic effects on cardiac function.

Deltazime is officially documented as an inhibitor of the CYP450 3A4 enzyme and the P-glycoprotein transporter. This pharmacokinetic action increases the systemic exposure of several co-administered medicines, including statins (e.g., Simvastatin), benzodiazepines (e.g., Midazolam), and immunosuppressants (e.g., Cyclosporine). Specific restrictions are mandated in the regulatory labeling: for example, the dosage of Simvastatin must be limited to 10 mg daily when taken concurrently, and the dosage of Ranolazine must also be limited.

Pharmacodynamic interactions are noted with other cardiovascular agents. Co-administration with beta-blockers is documented to cause additive effects on cardiac conduction, increasing the risk of AV block or bradycardia. Intravenous beta-blockers are formally classified as contraindicated for use with intravenous Deltazime. Co-administration with strong CYP3A4 inducers, such as Rifampin, is advised to be avoided as they may significantly reduce Deltazime's systemic exposure. Interactions with non-medicinal products are also documented: Grapefruit Juice can increase Deltazime's exposure, and alcohol consumption can alter the release of the extended-release formulation.

Mechanism of Action

Mechanism Overview: Blocking Calcium Ion Flow

Deltazime acts as an inhibitor (antagonist) of the L-type voltage-gated calcium channels ( L-VGCCs), which are the drug's primary biological targets in heart and vascular smooth muscle cells. The drug physically blocks the channels, preventing the influx of calcium ions ( Ca^2+) into the cytoplasm and initiating a downstream mechanistic cascade.

Modulating Vascular Resistance and Tone

In vascular smooth muscle cells, limiting the calcium influx reduces the molecular triggers necessary for actin-myosin cross-bridge formation. This results in the relaxation of the vascular walls (vasodilation). This physiological change reduces the systemic vascular resistance (the pressure against which blood flows), altering activity within the peripheral circulatory pathways.

Adjusting Myocardial Activity and Conduction

Within the myocardium, reduced Ca^2+ entry leads to a decreased force of contraction, lowering the heart's overall workload. Concurrently, the drug modulates the electrical signaling patterns in the specialized cardiac pacemaker cells. This mechanistic action results in a slower rhythm and altered electrical signal transmission within the cardiac conduction system.

Dosage and Administration Information

How Deltazime is Used: Official Administration Guidelines

Deltazime (Ceftazidime) is an antibiotic prescribed for parenteral (injectable) administration only, requiring supervision in a clinical setting. The use is strictly governed by detailed instructions for reconstitution, dosing, frequency, and population-specific adjustments as specified in regulatory prescribing information.


Administration and Dosing

Usage Parameter Official Instructions (Adult)
Route of Administration Intravenous (IV) injection/infusion or Deep Intramuscular (IM) injection.
Standard Unit Dose Typically 1 gram (g) or 2 g.
Standard Regimen 1 g every 8 hours (q8h) or 2 g every 12 hours (q12h), depending on the infection's severity.
Maximum Daily Dose Up to 6 g per day is typically recommended.
Preparation The medicine is a sterile, dry powder that must be reconstituted with a specified diluent before use. Solutions are administered as an IV infusion over approximately 30 minutes.

Population-Specific Dosing Rules

The dosage for Deltazime requires adjustment in specific patient groups, as the drug is almost entirely eliminated by the kidneys.

  • Renal Impairment: Dose reduction or frequency extension is mandatory for patients with impaired renal function, determined by their estimated Creatinine Clearance (CrCl). An initial loading dose of 1 g may be given before maintenance doses are adjusted (e.g., 1 g every 12 hours for CrCl 31–50 mL/min).
  • Older Adults: The daily dose for older adults, particularly those over 80 years of age, should not normally exceed 3 g.
  • Hepatic Impairment: No dosage adjustment is required for patients with hepatic dysfunction, provided their renal function is normal.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deltazime (Ceftazidime)

Evidence for Use in Complicated Intra-abdominal Infections (cIAI)

Research exploring Deltazime for complicated infections inside the abdomen was primarily conducted using large, controlled clinical trials in hospitalized adult patients. Studies examined specific outcomes related to physical discomfort (clinical response) and outcomes linked to inflammatory or irritative states (microbiological). The studies were designed to compare patterns of clinical and microbiological response against a standard treatment.

The evidence base largely consists of research for Ceftazidime when it is used in a combination product that includes another substance. Findings contribute to the broader evidence landscape by describing patterns observed in these studies regarding clinical and microbiological outcomes at a designated follow-up visit (Test-of-Cure). What remains uncertain is the full body of evidence regarding Ceftazidime used as a single agent in these complex infections, as the highest-level data comes from the combination product.

Evidence for Use in Hospital and Ventilator-Associated Pneumonia (HAP/VAP)

Research examined the use of the drug in critically ill patients with severe lung infections. These studies examined retrospective and prospective analyses. The key patient outcomes monitored were outcomes reflecting daily functioning or activity level (clinical response) and outcomes monitoring physiological strain or stress. The studies consistently focused on the use of Ceftazidime in combination when investigating infections caused by multi-drug resistant Gram-negative bacteria.

Long-term effects are not fully established beyond the short-term follow-up periods of the trials. Also, since this evidence is derived from severe, critically ill populations, the research provides context but does not determine whether an individual will respond similarly for all patients with HAP/VAP.

What Remains Unclear or Uncertain About the Evidence

Research highlights what is known—and what is still uncertain—about Deltazime. The highest-quality research, such as large randomized trials for major infections, overwhelmingly describes the use of Ceftazidime in combination with another drug. For this reason, the dedicated evidence for Ceftazidime used as a single agent for many severe infections is limited. Long-term effects are not fully established beyond the follow-up periods defined in the trials (typically 30 days), and data for certain groups remain insufficient.

Key Studies & References

  1. Ceftazidime Injection, Powder, Lyophilized, for Solution

Frequently Asked Questions (FAQ)

Common questions about Deltazime (FAQ)


Q: Can Deltazime be used during pregnancy?

A: Official information states that the use of this medication during pregnancy is not generally recommended. Conditional use is described only when a healthcare professional determines that the potential benefit to the patient outweighs the potential risk to the fetus.


Q: Can older adults use Deltazime safely according to official sources?

A: Regulatory documents define specific rules for using this medicine in older adults. For instance, the official daily dose should normally not exceed 3 g for those over 80 years of age. These guidelines define the specific conditions under which adjustments for older adults are described in the regulatory information.


Q: What type of research supports the use of Deltazime?

A: The evidence base supporting the uses of Deltazime primarily involves large, controlled clinical trials. These studies examined the drug in hospitalized patients, often when it was used as part of a combination product with another medicine.


Q: Does the evidence for Deltazime come from large studies?

A: Yes, authoritative research includes studies that were primarily conducted using large, controlled clinical trials in hospitalized patients. The findings from this research contribute to the official understanding of the drug's intended uses and profile.


Q: What information is available about stopping the use of Deltazime?

A: Official guidance emphasizes that the medication should be used for the full period prescribed, even if symptoms begin to improve before the end of treatment. This approach is described to manage the risks of incomplete treatment and the development of antibiotic resistance, consistent with official guidance.


Q: What are the signs of a serious side effect from Deltazime?

A: Serious reactions highlighted in regulatory documents include severe allergic reactions (anaphylaxis) and effects on the nervous system, such as seizures or profound confusion. Serious safety information commonly lists signs such as rash, hives, or sudden changes in alertness as potential manifestations of severe reactions.


Q: Can someone use Deltazime if they are taking multiple other prescription medications?

A: The drug is known to have interactions related to drug metabolism and heart function, which is documented in the official profile. Regulatory documents describe the importance of reviewing all co-administered medications to identify potential restrictions or dosage adjustments before use.


Q: Does Deltazime affect birth control pills?

A: Some authoritative medical sources note that certain types of hormonal contraceptives (birth control pills) may not work as effectively when used at the same time as this medication. Potential interactions with hormonal contraceptives are a topic that is described for review within regulatory contexts.


Q: How does Deltazime compare to older treatments for the same condition, based on evidence themes?

A: Clinical research has been designed to compare the observed patterns of patient response and outcomes against established, standard treatments. The studies often assess themes like non-inferiority (being not worse than) or superiority in treating specific infections.


Q: Can Deltazime affect lab test results?

A: Yes, official documentation advises that this medication may affect the results of certain laboratory tests. These include tests for liver enzymes and specific types of urine glucose tests used for diabetic patients.


Q: Is Deltazime available in different strengths?

A: The active component (Ceftazidime) is available in different stated amounts for reconstitution, such as 500 mg, 1 g, and 2 g vials. These different amounts are used to prepare the injectable solution tailored to the individual's needs.


Q: What happens if I miss a use of Deltazime?

A: According to official guidance, if a scheduled dose is missed, it should be used as soon as reasonably possible. If a dose is missed, official instructions describe skipping the missed dose when it is almost time for the next scheduled dose, thereby maintaining the intended schedule.


Q: How quickly does Deltazime typically start to have an effect?

A: Authoritative sources suggest that patients can typically expect to begin feeling better during the first few days of using the medicine. However, the time until improvement can vary, and this is not a universal experience for all patients.


Q: Is it common to feel tired after starting Deltazime?

A: Unusual tiredness or weakness is mentioned in some safety information related to this medicine. Asthenia, which is described as a lack of energy or strength, is listed as a potential uncommon or less common side effect.


Q: Does Deltazime interact with common over-the-counter pain relievers?

A: Regulatory data notes a potential minor interaction with salicylates, which are key components found in some over-the-counter pain relievers. This interaction could potentially lead to increased levels of the pain relievers in the body.


Q: Is Deltazime similar to [Name of another drug]?

A: Deltazime is officially categorized as a third-generation cephalosporin, which is a specific type of antibiotic belonging to the larger beta-lactam class. Other drugs are categorized and compared by their generation and class to understand their pharmacological relationships.


Q: Why does the official information say Deltazime should only be used for a short time?

A: The duration of use is generally short (typically 5 to 14 days) based on the design of the clinical trials that established its use. Using the drug for the shortest effective time helps to reduce risks, such as the potential for severe diarrhea linked to antibiotic use.


Q: Is Deltazime a controlled substance?

A: Deltazime is officially classified as a prescription-only (Rx-only) medicine. However, it is not listed as a controlled substance under the regulatory schedules that govern drugs with a high risk of dependence or misuse.


Q: Is Deltazime known to affect sleep patterns?

A: While changes to sleep patterns are not a commonly reported effect, official safety information reports that severe sleepiness is possible. This is often linked to other neurological effects, particularly if high drug concentrations occur, such as in patients with impaired kidney function.


Q: Are there any reported long-term effects from using Deltazime?

A: Research documents note that long-term effects are not fully established beyond the short follow-up periods defined in the clinical trials, which are typically about 30 days. The drug is primarily studied and intended for short-term use in acute infections.


Q: Does research indicate Deltazime is more effective for certain age groups?

A: Clinical trials for combination products containing the active ingredient have examined specific patient populations, including children from 3 months to less than 18 years of age. These studies are conducted to assess the drug's profile and appropriate use conditions across various age groups.


Q: Can I use other supplements while taking Deltazime?

A: General precautions in regulatory documents advise informing a healthcare provider of all other medications, dietary supplements, or herbal preparations being used. This practice allows for a review of any potential interactions, which is consistent with regulatory precautions.


Q: Does Deltazime interact with common herbal remedies?

A: Regulatory data notes that there is a potential for minor interaction with specific herbal remedies, such as Willow Bark and Rose Hips. This interaction could potentially lead to a higher level of the drug circulating in the body.


Q: Is it described as a cure or a management tool?

A: Deltazime is officially described as an anti-infective agent intended for the definitive elimination of susceptible bacterial pathogens. Its purpose is to address the root cause of the infection rather than solely managing symptoms.


Q: Why do some people say Deltazime didn't work for them?

A: Research documents state that study outcomes are not intended to 'determine whether an individual will respond similarly,' indicating known variability in patient response. Factors like the specific type of infection or the patient's condition can influence the outcome.


Q: Is it safe to drive or operate machinery while using Deltazime?

A: Official safety data lists side effects such as dizziness and other effects on the central nervous system. These documented effects could potentially impair the ability to drive, operate machinery, or perform tasks requiring full alertness.


Q: Is Deltazime known to cause changes in mood?

A: Some official reports of adverse reactions include mental or mood changes. These effects, such as confusion or irritability, are generally associated with the drug's documented effects on the central nervous system.


Q: Can Deltazime affect my blood pressure?

A: Official safety data has reported changes in blood pressure as potential cardiovascular side effects. Both elevated blood pressure (hypertension) and lowered blood pressure (hypotension) have been noted, though the frequency is not always specified.


Q: Is Deltazime a non-sedating medication?

A: Official safety information lists drowsiness or severe sleepiness as potential side effects. These effects are often noted, especially at high concentrations or in patients with impaired kidney function, which suggests it is not universally non-sedating.

How should Deltazime be stored and disposed of?

Storage Requirements

Deltazime (Diltiazem Hydrochloride) must be stored at Controlled Room Temperature, which is officially set between 20 C and 25 C (68 F and 77 F). Brief temperature excursions are permitted up to 30 C (86 F). The medication must be kept in the tightly closed container it came in and requires protection from moisture; therefore, storage areas with high humidity, such as bathrooms, should be avoided. A critical instruction from the official labeling is to keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Deltazime must be disposed of properly in accordance with local regulations. The official guidelines instruct that the medication should not be flushed down the toilet or poured down a drain unless specifically authorized. Instead, follow the non-flushable medication disposal guidance provided by regulatory authorities to ensure responsible discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deltazime found in:

A-Z Index: